Medicine and Pharmacology

Article
Medicine and Pharmacology
Immunology and Allergy

Diana Stafford

Abstract: Background. Patients evaluated for illness associated with water-damaged buildings are frequently offered HLA-DR/DQ typing, with results interpreted against a published table that labels certain haplotypes "mold susceptible" or "multisusceptible." That table belongs to the chronic inflammatory response syndrome (CIRS) framework, a proposed construct rather than an established diagnostic entity. Materials describing the framework state that approximately 24% of the population carries a susceptible type; no derivation of that figure was identified in the sources examined. Methods. Haplotypes were read from the publicly posted classification table and mapped to HLA-DRB1~DQB1 two-locus definitions. Because the table's DQ notation is internally inconsistent, two explicit readings were constructed. Carrier frequencies were calculated as 1 − (1 − Σp)² using National Marrow Donor Program frequencies, and tested against an independent British cohort, a United States organ-donor cohort, 1000 Genomes genotypes, family-phased haplotypes from the 17th International HLA and Immunogenetics Workshop, and 64 further world populations. Results. Under the broad reading, an estimated 88.4% of European Americans carry at least one listed haplotype; under the strict reading, 59.1%. Across four independent European-ancestry datasets the broad estimates range from 86.5% to 89.5%, while the strict estimates vary more widely, from 53.2% to 63.2%. Of 64 world populations with two-locus data, 28 met pre-specified data-completeness criteria; all 28 exceed 24% under the broad reading. The Hardy-Weinberg step was tested by direct enumeration of 2,690 individuals, where it overestimated carriage of the relevant DRB1 allele groups by 0.56 percentage points. Conclusions. Under both operational definitions, estimated carrier frequencies exceed 50% nationally, though they may overstate carriage of the original classifications where historical serological distinctions impose restrictions that two-locus data cannot resolve. The frequently cited 24% figure could not be reproduced from any dataset analyzed here; the originator attributes it to an unpublished clinical series. The comparison groups described in the literature reviewed, of 111 and 150 attendees, are clinic-based, and no source supplies a derivation connecting either to a national frequency. A positive result is informative only insofar as it is uncommon among people who do not have the condition. Taking the sensitivity values reported for the classification at face value, the carrier frequencies estimated here give positive likelihood ratios of 0.85 to 1.07 under the broad reading — a range containing 1.0, the value at which a positive result carries no information — and 1.3 to 1.6 under the strict reading.

Review
Medicine and Pharmacology
Immunology and Allergy

Ioanna Kotsiri

,

Eirini Papadakaki

,

Emmanouil Magiorkinis

Abstract: Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease in which interactions among the intestinal microbiome, bile acid metabolism, and immune regulation may influence disease pathogenesis, progression, and therapeutic response. This narrative review synthesizes clinical and experimental evidence concerning the microbiome-bile acid-immune axis and its relevance to emerging therapeutic strategies. Studies involving patients with PBC have identified alterations in intestinal microbial composition and diversity, disturbances in bile acid profiles, and microbial signatures associated with biochemical response to ursodeoxycholic acid. Microbiome-derived metabolites, including short-chain fatty acids, secondary bile acids, and tryptophan derivatives, may influence intestinal barrier integrity, bile acid receptor signaling, and innate and adaptive immune responses. However, much of the mechanistic evidence originates from experimental models or other liver and immune-mediated diseases, and causal relationships in human PBC remain incompletely established. Emerging peroxisome proliferator-activated receptor agonists, particularly elafibranor and seladelpar, have demonstrated biochemical efficacy, while the potential contribution of microbiome-mediated mechanisms to their therapeutic effects remains uncertain. Microbiome-directed interventions, including probiotics and fecal microbiota transplantation, remain investigational in PBC. Longitudinal multi-omics investigations, functional studies, and prospective biomarker validation are essential to establish clinically relevant mechanisms and evaluate opportunities for more personalized therapeutic approaches.

Review
Medicine and Pharmacology
Immunology and Allergy

Kotryna Linauskiene

,

Laura Malinauskiene

,

Kestutis Cerniauskas

,

Anzelika Chomiciene

,

Edita Gasiuniene

,

Brigita Gradauskiene

Abstract: Background and Objectives: Secondary hypogammaglobulinemia (SHG) is common in hematologic malignancy, transplantation, and B-cell- or plasma-cell-directed therapy. Because secondary antibody deficiency (SAD) can occur despite near-normal total IgG, thresholds for investigation and immunoglobulin replacement therapy (IgRT) remain inconsistent. Materials and Methods: The 2023 Lithuanian consensus was developed by seven allergologists and clinical immunologists from two tertiary academic centers. Six authors updated it through targeted PubMed/MEDLINE searches and review of professional-society, regulatory, and national guidance in August 2026. Evidence selection prioritized guidelines, reviews, comparative studies, and real-world data. This was a structured narrative review and expert consensus without GRADE assessment or Delphi voting. Results: Twenty-nine recommendations address assessment, infection, IgRT initiation and dosing, route, safety, monitoring, home treatment, and withdrawal. Decisions integrate infection burden, IgG concentration, specific-antibody function, comorbidity, lung disease, ongoing immunosuppression, and expected immune recovery. A usual starting dose is 0.4–0.6 g/kg/month, individualized to clinical response. Active infection is not an absolute contraindication to IgRT. Conclusions: These recommendations provide a practical Lithuanian approach to SAD and SHG and support individualized use of intravenous, conventional subcutaneous, and facilitated subcutaneous IgRT rather than treatment based solely on an IgG threshold.

Review
Medicine and Pharmacology
Immunology and Allergy

Buzhe Zhang

,

Tian Lan

Abstract: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Image-guided ablation is a curative-intent option for selected patients with early-stage disease. Cryoablation enables real-time visualization of the ice ball and may preserve antigenic structures, prompting interest in a potential in situ vaccination strategy. This review summarizes clinical comparisons with radiofrequency ablation (RFA) and microwave ablation (MWA), evidence on cryoablation combined with transarterial chemoembolization (TACE), and research on immune mechanisms and combination strategies. Comparative data suggest effectiveness broadly similar to thermal ablation, with context-specific procedural advantages; a general survival benefit has not been demonstrated. Preclinical and mechanistic studies suggest freeze–thaw injury can release tumor antigens and damage-associated molecular patterns, supporting dendritic-cell activation and T-cell priming. Counter-regulatory pathways may nevertheless limit systemic responses. Evidence on combining cryoablation with immune checkpoint inhibitors is predominantly preclinical, with clinical reports limited to small, heterogeneous studies. Current evidence supports cryoablation as a local treatment with immunological potential, but not as stand-alone immunotherapy. Future studies should evaluate treatment quality, ablative margins, tumor immune context, candidate biomarkers, and treatment sequencing.

Hypothesis
Medicine and Pharmacology
Immunology and Allergy

Mario José do Canto Filho

Abstract: Type 1 diabetes (T1D) is a staged, heterogeneous autoimmune disease in which immune injury, inflammatory signaling, antigen presentation, beta-cell stress, and loss of regulatory control interact over time. Human intervention studies establish that the disease course can be modified, yet benefits are commonly partial, heterogeneous, or treatment-dependent, and durable treatment-free tolerance remains uncommon. This article integrates randomized and prospective T1D trials, long-term follow-up, human mechanistic studies, negative and transient therapeutic studies, contemporary beta-cell-directed interventions, and cell-replacement evidence to examine why biological activity at individual targets has not consistently produced durable system control. Our central hypothesis is that, because the dominant biological bottleneck can change over time, a conditional multi-step treatment strategy that sequentially targets measured residual mechanisms may achieve greater and more durable disease modification than a single-agent strategy directed at one target alone. This does not imply indiscriminate polytherapy: each additional step should be entered only when a defined biological objective remains unmet and should be withdrawn when its task is complete. We therefore propose a conditional statetransition framework comprising seven research operations: baseline staging and stabilization; finite immune induction; optional immune-recovery control; mechanism-directed continuation or finite reinforcement; tolerance consolidation; withdrawal and surveillance; and mechanismmatched reintervention or transition to beta-cell replacement. A parallel beta-cell axis is selected independently to address metabolic load, tissue stress, and recoverable function. The framework is not a treatment protocol and the superiority of the proposed multi-step strategy has not been clinically established. It is a falsifiable hypothesis intended to generate component-controlled trials that directly compare state-guided sequencing with appropriate monotherapy or inductionalone controls.

Hypothesis
Medicine and Pharmacology
Immunology and Allergy

Harriet A. Carroll

Abstract: Background: Myalgic encephalomyelitis (ME) is a severely debilitating neuroimmune disease with the characteristic feature of post-exertional malaise (PEM). Whilst multiple studies have found various abnormalities, there is significant heterogeneity in findings; as such there is no consensus regarding the underlying aetiology. Mast cells are immune cells most commonly recognised for their role in allergy. The scope of biological effects mast cells have is growing in recognition, with inappropriate mast cell degranulation increasingly recognised to cause a range of symptoms and downstream effects. Hypothesis: ME may be a mast cell activation disorder variant, with exertion being the primary trigger to inappropriate mast cell degranulation, possibly due to mast cell hypersensitivity to metabolically produced reactive oxygen species. Mast cell activation releases mitochondrial components which further act as an “autopathogen”, whilst each degranulation cycle reduces mast cell metabolic flexibility. This cycle is perpetuated in those with genetic susceptibility towards Th2-dominance, which acts to both impede pathogen clearance and drive autoinflammation. The resultant chronic immune activation triggers immune and host metabolic changes resembling sickness metabolism. This causes a range of multisystemic symptoms, worsened by exertion, akin to a chronic sickness behaviour. Due to the close and bidirectional interactions between mast cells, the nervous system, and mitochondria, such a hypothesis can potentially explain various aspects of ME, such as: Why ME can be caused by a range of exposures; the core symptoms of ME; individual variances in clinical presentations; why pacing can prevent worsening; and time trends and symptoms of PEM. Several potential counterarguments are also discussed, along with methods to try and test the hypothesis. Conclusion: Several lines of evidence suggest it is at least plausible that (a subgroup of) ME could be a unique and distinct variant of a mast cell activation disorder. As the immune system and metabolism are intrinsically linked, it could be argued this is an immunometabolic mast cell disorder phenotype. However, this is one of many plausible hypotheses, requires testing and validation, and does not change the current recommendations for managing ME, nor should it be used as evidence that the aetiology of ME is established.

Review
Medicine and Pharmacology
Immunology and Allergy

Jie Wang

,

Deying Li

,

Xianghong Peng

,

Zhi Song

,

Linyan Tang

Abstract: Neurotransmitters, including acetylcholine (ACh) and dopamine, play critical roles in regulating immune cell function and inflammatory responses across various pathologies. Beyond its classical neuronal role, ACh is actively secreted by diverse immune populations, including T cells, B cells, macrophages, dendritic cells, and natural killer cells. Upon binding to nicotinic (nAChRs) and muscarinic (mAChRs) acetylcholine receptors expressed on neutrophils, T cells, B cells, and monocytes/macrophages, ACh triggers intracellular signaling pathways that modulate immune cell proliferation, polarization, and cytokine secretion. Similarly, dopamine receptors (D1R–D5R) are widely expressed across these identical immune cell subsets. Dopamine signaling dynamically orchestrates immune cell proliferation, differentiation, activation, migration, polarization, and cytokine profiles. Consequently, these neurotransmitter-mediated pathways play pivotal roles in the pathogenesis of neurodegenerative, autoimmune, and systemic inflammatory diseases, including Parkinson’s disease, multiple sclerosis, inflammatory bowel disease, acute pancreatitis, chronic obstructive pulmonary disease, acute respiratory distress syndrome, infective endocarditis, and rheumatic heart disease.

Review
Medicine and Pharmacology
Immunology and Allergy

Yunwang Zhao

,

Hongxian Cheng

,

Shiyi Zhou

,

Lei He

,

Chenlin Xiu

,

Baihai Huang

,

Xiongxiong Lu

Abstract: Circular RNAs (circRNAs) were, until a decade ago, a by-product of transcriptome profiling. They are now drug candidates. A covalently closed backbone removes the termini that exonucleases and cap-dependent decay require, and lipid nanoparticles (LNPs) turn that molecular property into a pharmacological one by carrying the RNA into the cytoplasm of a chosen cell. Between 2021 and 2026 the field moved from reporter-gene proof of concept to nine first-in-human programmes, five of which encode a CD19 chimeric antigen receptor and one of which has completed. We argue that the central question is no longer whether circRNA can be made and delivered, but which of its claimed advantages survive in vivo, and at what cost in manufacturing complexity. We examine performance determinants at three coupled levels, the molecule, the particle and the biological context, and set out the manufacturing, analytical and regulatory problems that will decide whether circularity becomes a general platform property or a niche solution.

Hypothesis
Medicine and Pharmacology
Immunology and Allergy

Michael Moran

Abstract: Passive transfer studies show that immunoglobulin G (IgG) from some people with Long COVID can induce neurological abnormalities in mice. These findings support pathogenic IgG activity in experimental systems, but do not establish the antibody source, its necessity for ongoing human illness, or the reversibility of established injury. I propose that, in a subgroup with neuropathic or autonomic manifestations and reproducible pathogenic IgG activity, long-lived plasma cells contribute to persistent disease and may represent a target for durable remission. This proposal contains three separable hypotheses: IgG contributes to disease; a persistent plasma-cell compartment maintains the relevant IgG; and reducing that compartment improves clinical outcomes. Negative trials of antibody-directed interventions constrain these hypotheses and cannot be dismissed solely as failures of patient selection or transient antibody removal. A staged program should first validate functional assays against experimental pathogenicity, then investigate antibody production and persistence, and only then undertake a biomarker-enriched randomized trial with adequate safety oversight. Clinical efficacy should be assessed by a prespecified between-group comparison, with longitudinal antibody activity and target engagement providing supporting mechanistic evidence. Durable clinical improvement would support further development but would not, by itself, prove a long-lived plasma-cell mechanism. This manuscript proposes research; it reports no new patient data and does not establish a treatment for Long COVID.

Article
Medicine and Pharmacology
Immunology and Allergy

Alyssa Pekonidi

,

Nikita Sergeev

,

Аrtem Fedorinin

,

Dmitry Laptev

,

Margarita Samsonova

,

Maria Terekhova

,

Ivan Golodnikov

,

Arina Sleptsova

,

Larisa Nikankina

,

Anna Ivanova

+10 authors

Abstract: Background: Type 1 diabetes mellitus (T1DM) is characterised by substantial heterogeneity in clinical manifestations, the rate of β-cell destruction, and diabetes-associated autoantibody (DAA) profiles across individuals of different ethnic backgrounds and ages. We investigated the immunological heterogeneity of T1DM through immunophenotyping of major lymphocyte populations using multiparameter flow cytometry. Results: T1DM associates with distinct immunophenotypes dependent on age, disease stage, DAA profiles, and the presence of Diabetic Ketoacidosis (DKA). Paediatric T1DM (n = 49) shows attenuated innate immunity (fewer NK and MAIT cells) alongside higher T-cell activation. Adult T1DM (n = 55) features remodelling in NK-cell receptor landscape, specifically expanding CD8+, CD38+, CD161+, and NKG2A+ NK-cell subsets. Long-standing T1DM (n = 28) combines higher CD8+ T-cell cytotoxicity with lower NK-cell cytotoxicity. High Autoantibody / Multi-antibody T1DM is marked by fewer CD8+ T cells, B cells, protective NKregs, and MAIT cells, but more CD38+ NK cells. Seronegative / Low Antibody T1DM shows a drop in total NK and NKeff cells, but an expansion of inhibitory, CD56bright, and CD8+ NK subsets. Paediatric DKA is linked to fewer innate-like T cells and more activated T cells. Adult DKA is characterized by drops in various NK cells (CD3-CD56+, CD3-CD8+, NKeff) and specific T cells (CD8+CD161+ and CD161+ double-negative). Conclusions: The immunological heterogeneity identified in patients with T1DM underscores the importance of patient stratification, which may facilitate the discovery of predictive and prognostic cellular biomarkers capable of estimating the rate of progression to clinically manifest T1DM and the risk of an aggressive disease course, respectively.

Review
Medicine and Pharmacology
Immunology and Allergy

Alexandru-Florinel Oancea

,

Mathilde Leonard

,

Gina Botnariu

,

Ionela-Larisa Miftode

,

Alexandru Burlacu

,

Andrei Vâță

,

Gabriela Crăciun

,

Alexandra Rotaru

,

Raluca Mitea

,

Daniela Maria Tanase

+2 authors

Abstract: Hepatocellular carcinoma (HCC) develops through cooperation between altered hepatocytes, chronic liver injury and a stromal and immune environment. Genomic alterations and signaling abnormalities provide a rationale for treatment development, but pathway activation rarely identifies therapeutic dependence alone. This narrative review connects hepatic stellate-cell states, tumor-cell plasticity, genomic instability and four major signaling pathways with antigen presentation, immune exclusion and clinical treatment evidence. Targeted searches were updated through 6 October 2026, retaining foundational work and prioritizing recent studies. Single-cell and spatial analyses reveal that stellate cells and cancer-associated fibroblasts can exert opposing effects according to their state and location. Similarly, CTNNB1-associated signaling can favor immune exclusion, but mutation status does not fully capture immune context or establish universal resistance to checkpoint combinations. Intratumoral dendritic-cell and lymphocyte organization, suppressive myeloid niches and humoral responses provide complementary explanations of treatment heterogeneity. Randomized trials support selected antiangiogenic and checkpoint combinations in unresectable HCC, while negative trials and updated adjuvant results demonstrate the limits of extrapolating biological rationale across regimens and disease stages. The synthesis distinguishes experimental causality, patient-level association and clinically validated benefit. Translation requires compartment-specific target assessment, representative sampling and prospective biomarker evaluation within a defined treatment setting, alongside assessment of liver reserve.

Review
Medicine and Pharmacology
Immunology and Allergy

Yunwang Zhao

,

Hongxian Cheng

,

Shiyi Zhou

,

Lei He

,

Chenlin Xiu

,

Baihai Huang

,

Xiongxiong Lu

Abstract: Lipid nanoparticle (LNP)-mRNA vaccines compressed the path from pathogen sequence to licensed product into less than a year and are now approved for two diseases, with more than twenty indications in clinical development. The platform's potency is no longer in doubt; its predictability is. We argue that progress is now limited by three interfaces that are engineered largely independently: the lipid-RNA interface, which sets encapsulation, internal structure and storage stability; the particle-cell interface, which sets tropism and the efficiency of endosomal escape; and the particle-immune interface, which sets the balance between adjuvanticity and reactogenicity. Quantitative design rules exist for the first interface, remain empirical for the second, and are almost absent for the third, which is why formulation development still proceeds by screening rather than by calculation. We review the molecular design of the mRNA payload, the chemistry, manufacture and intracellular trafficking of LNPs, the immunological chain that links innate activation to germinal-centre output, and the clinical evidence across COVID-19, respiratory syncytial virus, influenza, cytomegalovirus, HIV and other targets. We conclude by identifying the measurements and design rules that would make the next generation of LNP-mRNA vaccines predictable rather than empirical.

Article
Medicine and Pharmacology
Immunology and Allergy

Ralph Mösges

,

Hanna Christina Verfürth

,

Jens Umlauf

,

Edmund Curtius

,

Julia Blankartz

,

Silke Allekotte

,

Hacer Sahin

,

Cengizhan Acikel

,

Andreas Bilstein

,

Mirko Meisberger

+5 authors

Abstract: Background/Objectives: Drug-free nasal formulations may provide an alternative or adjunct to pharmacological treatment in patients with allergic rhinitis. This study in-vestigated the clinical performance, tolerability, and safety of a hypertonic nasal spray containing hydroxypropyl-β-cyclodextrin (BDNS) compared with 0.9% isotonic saline in adults with pollen-induced allergic rhinitis. Methods: This prospective, randomised, double-blind, controlled, two-period crossover study included 32 adults with pollen-induced allergic rhinitis. Participants were randomised 1:1 to receive BDNS followed by isotonic saline or the reverse sequence, with each treatment administered for 7 days. The primary endpoint was the mean Lebel Symptom Score following standard-ised nasal allergen provocation testing after each treatment period. Secondary out-comes included individual symptom scores, peak nasal inspiratory flow, nasal sensory tolerability, treatment satisfaction and preference, and safety. The primary analysis was conducted in the per-protocol set using a linear mixed-effects model. Results: All 32 randomised participants completed the study, and 30 were included in the per-protocol set. The adjusted least-squares mean Lebel Symptom Score was 3.33 after BDNS and 4.30 after isotonic saline. BDNS met the prespecified criterion for non-inferiority and subsequently demonstrated superiority over isotonic saline, with a mean treatment difference of −0.97 points in the per-protocol population (p = 0.026). The analysis in the randomised set yielded consistent findings (mean difference, −0.87 points; p = 0.033). Treatment satisfaction was significantly higher with BDNS for both perceived effectiveness (difference, 0.69; p = 0.007) and tolerability (difference, 0.81; p < 0.001). Overall, 75% of participants preferred BDNS. No serious treatment-emergent adverse events or serious adverse device effects occurred, and no device deficiencies were reported. Conclusions: In adults with pollen-induced allergic rhinitis, BDNS was non-inferior and, following hierarchical testing, superior to 0.9% isotonic saline with respect to post-provocation symptom severity after 7 days of treatment. BDNS was well tolerated and was associated with greater participant satisfaction and a clear treatment preference. These findings support the favourable short-term clinical per-formance and acceptability of BDNS under controlled allergen-challenge conditions.

Article
Medicine and Pharmacology
Immunology and Allergy

Yue Wu

,

Jie Ren

Abstract: Background and objective: Uveitis is a group of immune-mediated inflammatory diseases of the eye and remains one of the leading causes of preventable visual loss in working-age adults, with relapsing and treatment-refractory phenotypes closely tied to disturbed peripheral myeloid immune homeostasis. Conventional type 2 dendritic cells (CD1c+ cDC2) sit at the junction between JAK-STAT cytokine signaling and antigen presentation, yet systematic work that quantifies this axis into a reproducible, falsifiable, and explicitly evidence-graded candidate set remains scarce. The present study therefore set out to decode the molecular pattern of the JAK-STAT axis in peripheral blood CD1c+ cDC2 cells from patients with uveitis and, while explicitly annotating the strength of each layer of evidence, to prioritize a candidate-target panel that can guide subsequent wet-laboratory work. Methods: With GEO dataset GSE194060 (28 uveitis and 14 healthy-control samples of sorted CD1c+ cDC2 cells) as the discovery cohort and the 168 genes of KEGG hsa04630 (JAK-STAT signaling) as a fixed molecular axis, we deployed an end-to-end pipeline: differential expression and three-way intersection (expression layer) → cis-instrument inverse-variance weighted (IVW) Mendelian randomization with FinnGen R12 iridocyclitis as the outcome (genetic-association layer) → consensus clustering and immune-microenvironment profiling → candidate locking by the intersection of LASSO, random forest, and SVM-RFE (machine-learning layer) → multi-cohort single-gene diagnostic modeling of STAM2 → aqueous-humor single-cell atlas and cell-cell communication → myeloid pseudotime and computational perturbation → qPCR, DrugReflector active-learning virtual screening, and molecular docking. Each layer was reported against its prespecified thresholds; the primary DrugReflector signature was evaluated by 200 sample-level bootstrap resamples, Mendelian randomization by leave-one-out analysis, and the remaining layers by the sensitivity analyses prespecified for each layer. Results: At the expression level, 3,301 nominally differential genes, the 168 JAK-STAT axis genes, and 3,872 uveitis-associated genes converged on an 18-gene intersection that included IL10 and PDGFB. At the genetic-association level, IVW analysis identified 20 genes at nominal significance (p< 0.05), 8 of which passed Benjamini-Hochberg FDR (q< 0.05); IL10 (q= 0.1246), STAM2 (q= 0.1246), and PDGFB (q= 0.1573) reached nominal significance only, without passing FDR correction, and are reported as nominal associations. The intersection of the three machine-learning algorithms converged on the three transcripts IL10 / PDGFB / STAM2. A STAM2 single-gene diagnostic model reached an AUC of 0.7883 in the training cohort and 0.8056 and 0.8000 in two independent myeloid/monocyte cohorts (a same-study audit cohort yielded 0.6288 and is used for sensitivity analysis only). The aqueous-humor single-cell atlas resolved 37,664 cells, 18 clusters, and 20 cell types; STAM2 myeloid pseudotime identified four differentiation states; and computational perturbation placed STAM2 among the most sensitive nodes (|Z|=5.17). DrugReflector active learning identified a single compound, BRD-K11973162 (probability 0.1591), exceeding the prespecified reversal-probability threshold of 0.10 among 9,597 compounds. In the LPS-stimulated THP-1 myeloid inflammation model, qPCR showed significant up-regulation of all three candidates relative to unstimulated controls (IL10, 1.5365-fold, p=3.17×10⁻³; PDGFB, 1.6592-fold, p=4.76×10⁻⁵; STAM2, 1.8220-fold, p=1.95×10⁻⁵; n=3 per group, n=3+3 total). Conclusion: In uveitis peripheral CD1c+ cDC2 cells, this study delineates a JAK-STAT-centered IL10–PDGFB–STAM2 candidate panel defined by an integrated chain of expression, genetic-association, machine-learning, single-cell, and in vitro evidence, and proposes BRD-K11973162 as the sole computationally prioritized candidate compound under the prespecified reversal-probability threshold. The computational and single-cell results are computational inferences; qPCR provides experimental support at the level of relative mRNA expression in LPS-stimulated THP-1 cells and does not address protein levels, cellular function, or clinical diagnostic performance. The candidate panel and its causal direction still require confirmation in prospective multicenter cohorts and functional experiments.

Article
Medicine and Pharmacology
Immunology and Allergy

Yue Wu

,

Jie Ren

Abstract: Background: Abdominal aortic aneurysm (AAA) is characterised by irreversible dilatation of the abdominal aorta and a risk of rupture. Clinical assessment still relies mainly on diameter and growth rate and does not capture the immune, vascular and matrix heterogeneity of the aortic wall. Protein S-palmitoylation is catalysed by ZDHHC palmitoyltransferases and reversed by depalmitoylating enzymes. It regulates membrane localisation and trafficking of immune receptors, chemokine receptors, ion channels and vascular signalling proteins. However, whether palmitoylation-related machinery and substrates jointly define an AAA disease axis has not been systematically examined. This study aimed to identify a reproducible palmitoylation-related module in human AAA tissue, to screen axis-level cis-eQTL multiplicity-controlled significant genes and to independently define the strict genetic effect boundaries of that module at a cis-eQTL layer, to converge the module onto core targets using multi-omics, machine learning, single-cell analysis and computational docking, and to validate the hub genes at the tissue-expression level by real qPCR. Methods: We used GSE232911 (110 patients with AAA and 13 donors) as the discovery cohort and assembled an S-palmitoylation machinery-and-substrate axis gene set. A tissue-level module was frozen from the intersection of differential expression, the axis gene set and pre-specified AAA vascular and inflammatory programmes. We then performed axis-level cis-eQTL Mendelian randomisation (MR) screening with Benjamini-Hochberg FDR and Bonferroni double correction to select multiplicity-controlled significant genes, together with independent validation at a strict cis-eQTL layer with coloc.abf colocalisation; disease-internal consensus clustering; LASSO, random forest and SVM-RFE feature selection within the frozen module; a single-gene logistic model with two external directional checks; construction of the GSE166676 single-cell atlas; myeloid monocle3 trajectory and scTenifoldKnk in-silico perturbation; L1000CDS2, CTD, P2Rank and AutoDock Vina public-resource integration and computational docking; and real qPCR validation of CD80 and HTR2B. Results: The discovery cohort yielded 3,100 differentially expressed genes. The frozen three-way intersection produced a 15-gene module, including 12 up-regulated and 3 down-regulated genes. In the axis-level cis-eQTL screening layer, 161 of the 341 axis genes were estimable, and 42 reached nominal significance (IVW random-effects p<0.05); after Benjamini-Hochberg FDR and Bonferroni double correction, 9 genes simultaneously satisfied q<0.01 and p<0.05/161 and constitute the multiplicity-controlled significant genes: SORT1, BAALC, ZDHHC6, MICA, CD7, CANX, PI4K2A, GSDMD and ADORA2B (five risk-increasing and four risk-decreasing, all p<0.001). In the independent strict cis-eQTL layer (341 axis genes, 35 passing the r²<0.001 instrument gate, 15 estimable), ENTPD1 (OR 0.884, 95% CI 0.790-0.989, p=0.031) and NOD2 (OR 0.942, 95% CI 0.888-0.998, p=0.042) reached nominal significance but none passed BH-FDR<0.05 (minimum q=0.317); single-SNP and leave-one-out analyses quantified the instrument-contribution boundaries of the two signals. None of 106 coloc.abf tests showed strong colocalisation, and the outcome-region audit showed limited AAA GWAS signal in the relevant windows (Figure S1 ). AAA tissue resolved into K=3 disease-internal molecular groups (C1=40, C2=55 and C3=15). The three machine-learning methods uniquely converged on CD80 and HTR2B. The single-gene CD80 model had a training AUC of 0.9685 and remained directionally consistent in two external cohorts (AUC 0.7551 and 0.7449). The single-cell atlas retained 7,596 cells, and the myeloid perturbation converged on cytokine-cytokine receptor interaction (KEGG, k=9/50, FDR=0.00355). The druggability layer returned 38 unique perturbagens, 29 high-evidence CD80-related compounds and computational docking for both targets; the best mode-1 affinities were -7.46 kcal/mol for CD80 and -8.98 kcal/mol for HTR2B. Real qPCR showed higher CD80 (1.54-fold, p=0.0032) and HTR2B (1.66-fold, p=4.8x10^-5) expression in AAA tissue than in donor tissue. Conclusion: We delineate an S-palmitoylation-contextualised immune-vascular disease axis in human AAA and place CD80 and HTR2B at the intersection of multi-omics screening, computational perturbation, computational docking and real qPCR tissue validation. The genetic layer returned nine multiplicity-controlled significant genes at the axis-level screen and retained two nominal associations with their full correction boundaries at the independent strict layer. The single-cell, perturbation and docking layers provide mechanistic and druggability directions, and qPCR provides expression-level validation in human aortic tissue. Collectively, the evidence supports a testable palmitoylation-immune costimulation-vascular inflammation axis and establishes an executable framework for functional and cohort validation.

Review
Medicine and Pharmacology
Immunology and Allergy

Estefania Vásquez Echeverri

,

Kathleen E. Sullivan

Abstract: Inborn errors of immunity (IEI), which includes primary immunodeficiencies, are a heterogenous group of disorders that affect the immune system leading to infections, autoimmunity, atopy, inflammation, or malignancy. The most recent update by Inter-national Union of Immunological Societies (IUIS) reports more than 500 gene defects in 10 categories. The initial approach to diagnosis should be dictated by the clinical history and physical examination. Traditional laboratory studies and genetic testing represent the backbone of diagnostic testing. The treatment options depend on the specific disorder and include support measures, immunoglobulin replacement therapy, antibiotic prophylaxis, immunosuppression, biological therapy, hematopoietic stem cell transplantation, and gene therapy. The early clinical suspicion and expeditious testing contribute to im-proved outcomes. This review provides a general approach to patients with suspected IEIs, highlighting aspects of infections and non-infectious manifestations, clinical history, physical examination, and immune laboratories, functional and genetic evaluation.

Review
Medicine and Pharmacology
Immunology and Allergy

Alexey Lupatov

,

Irina Pokusaeva

,

Irina Kholodenko

,

Marina Shestakova

,

Kirill Larin

,

Rita Khusainova

,

Ildar Minniakhmetov

,

Vladimir Chekhonin

,

Konstantin Yarygin

,

Natalia Mokrysheva

Abstract: Type 1 diabetes mellitus (T1D) is an autoimmune disease driven by a complex interplay between genetic susceptibility, environmental factors, and dysregulated immune re-sponses, ultimately leading to the progressive destruction of insulin-producing pancre-atic β-cells. Despite substantial advances in glucose monitoring and insulin delivery technologies, current treatment strategies cannot fully reproduce the physiological regu-lation of insulin secretion and do not directly target the underlying autoimmune process. Consequently, increasing attention has been directed toward immunomodulatory ap-proaches aimed at preserving residual β-cell function and modifying disease progres-sion. Mesenchymal stromal cells (MSCs) have emerged as a promising cell-based thera-peutic approach owing to their broad immunomodulatory, anti-inflammatory, and paracrine properties. Importantly, unlike therapies directed predominantly at individual immune targets or pathways, MSCs can simultaneously modulate multiple intercon-nected mechanisms involved in T1D immunopathogenesis, affecting both innate and adaptive immune responses, inflammatory signaling, antigen presentation, and immune tolerance. This broad and multifaceted mode of action provides a strong rationale for in-vestigating MSCs as a therapeutic strategy capable of addressing the complex and highly interconnected nature of T1D autoimmunity. This review examines the major mecha-nisms underlying T1D immunopathogenesis and the multifaceted immunomodulatory effects of MSCs, followed by a critical evaluation of the available preclinical and clinical evidence on MSC-based therapy. The potential of MSCs to preserve β-cell function, mod-ulate immune responses, and improve metabolic outcomes is considered, together with current limitations and challenges for clinical translation.

Review
Medicine and Pharmacology
Immunology and Allergy

Juan Bautista De Sanctis

,

Alexis Hipólito García

Abstract: This narrative review examines recent literature on human genetic variation and the clinical spectrum of dengue. A comprehensive search through September 2026 synthesized findings from genetic association studies, HLA typing, and genome-wide studies. The evidence is systematically categorized according to the World Health Organization clinical classification. The majority of available data derive from investigations conducted in Southeast Asia, with limited contributions from Africa and Latin America. Notably, specific HLA alleles—particularly HLA-A*24—as well as MICB and PLCE1 gene variants demonstrate the strongest associations with severe dengue; however, these associations vary by population and viral serotype. Other immune response genes, including CD209, FCGR2A, and TNF, have also been implicated, although their effects exhibit inconsistency across diverse cohorts and epidemiological settings. Conversely, the impact of certain variants, such as FCGR2A R/R131, appears to be modulated by population context, infecting serotype, and infection history. A major limitation of the existing body of research is the prevalence of small sample sizes, heterogeneity in case definitions across guidelines, and insufficient adjustment for genetic diversity. To date, no genetic marker has been validated for routine clinical use on a global scale; nevertheless, large-scale genetic analyses have yielded novel insights that warrant further investigation in large, multi-ethnic studies integrating both host and viral genomic data. Genetic analyses are crucial for improving vaccine efficacy and for identifying therapeutic targets to prevent dengue infection and reduce the risk of severe disease.

Review
Medicine and Pharmacology
Immunology and Allergy

Tolu Osoba

,

Christie Okonkwo

Abstract: Objective. To systematically evaluate the interface between vaccination and the gut-brain axis (GBA) in both directions of effect: first, whether vaccines or their components alter GBA biology, including microbiome composition, barrier integrity, cytokine responses, and mitochondrial function; second, whether pre-existing GBA state modifies the response to vaccination; and third, whether either direction bears on neurodevelopmental outcomes or on the adverse events recorded in trials and surveillance. Data Sources. PubMed and Google Scholar were searched directly, and the Walden University Library federated discovery service was used to search its subscribed collections, including MEDLINE, Embase, Cochrane, CINAHL, Scopus and ScienceDirect, from inception to 5 September 2025. Eligibility Criteria. Human and animal studies examining licensed vaccines or vaccine components with measurable outcomes in GBA domains, neurodevelopmental endpoints, or post-marketing adverse events. Results. Of 3,047 records, 60 studies met inclusion criteria in the primary search, with a further 7 identified through a targeted supplementary search to September 2026, giving 67 included studies, listed in Appendix A. Microbiome composition influenced vaccine immunogenicity: higher Bifidobacterium abundance predicted stronger infant antibody responses, and neonatal antibiotic exposure reduced antibody titres to several infant vaccines measured at 7 months of age. Evidence on whether vaccination itself alters the microbiome is limited: one longitudinal adult cohort reported compositional stability, pediatric data are close to absent, and transient shifts have been observed in mice. Animal maternal immune activation models implicated IL-6 and IL-17A pathways in neurodevelopmental alterations, whereas maternal vaccination showed no such association. Cohorts exceeding one million children found no association between autism and the vaccine exposures they measured, principally measles-mumps-rubella vaccination, thimerosal and cumulative antigen count, consistent with a 2025 Danish cohort of aluminium-adsorbed vaccine exposure and a December 2025 WHO advisory reaffirmation. No study identified examined DTaP, hepatitis B or varicella in relation to neurodevelopmental outcomes. Few eligible studies directly assessed barrier or mitochondrial endpoints. Active surveillance quantified specific adverse events, including febrile seizures, intussusception, immune thrombocytopenic purpura, myocarditis (lower with 2023-2024 mRNA formulations), and anaphylaxis. Conclusions. The two directions of effect at this interface are supported to very different degrees, and that asymmetry is the principal finding. Evidence that gut microbiome state modifies vaccine response is moderate in certainty. Evidence on whether vaccination alters gut-brain axis biology, the direction the causal hypotheses in this field assert, is thin rather than negative: barrier, mitochondrial and paediatric data are essentially absent, and the single relevant longitudinal cohort concerns adults receiving COVID-19 mRNA vaccines. Large-scale epidemiology does not support vaccine-attributable increases in autism risk for the exposures those cohorts measured, principally measles-mumps-rubella vaccination, thimerosal and cumulative antigen count; it does not address the microbiome pathway. Several rare adverse events are quantifiable through active surveillance, whereas others remain uncertain signals. Continued active surveillance and transparent risk communication remain essential.

Review
Medicine and Pharmacology
Immunology and Allergy

Jingyu Yang

,

Yuehong Chen

,

Yulin Zhang

,

Qibing Xie

,

Geng Yin

Abstract: Interferon (IFN)-induced protein 6 (IFI6) is an important member of the IFN-stimulated gene (ISG) family, mainly enriched in the inner mitochondrial membrane and endoplasmic reticulum (ER). It plays significant roles in anti-apoptosis, immune regulation, maintenance of mitochondrial homeostasis, antiviral defense, and promotion of tumor progression. At the molecular mechanism level, IFI6 inhibits mitochondrial membrane depolarization, cytochrome c release, and caspase activation. It also regulates the B-cell lymphoma 2 (Bcl-2)/Bcl-2 interacting mediator of cell death (Bim) expression balance, activates the janus kinase (JAK)/signal transducer and activator of transcription (STAT) and phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) pathways, and inhibits the degradation of ferroptosis-related proteins solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), thereby enhancing cell survival and proliferation through multiple pathways. In terms of immune regulation, IFI6 also affects immune cells (such as T/B cells, etc.) and the tumor microenvironment. IFI6 regulates mitochondrial reactive oxygen species (mtROS) and mitochondrial calcium homeostasis, influencing respiratory chain assembly and metabolism. In terms of virus regulation, IFI6 may inhibit the replication of multiple viruses (such as hepatitis B virus (HBV), hepatitis C virus (HCV), SARS-CoV-2, etc.) by inhibiting flavivirus-induced ER invagination, interfering with retinoic acid-inducible gene I (RIG-I)-like receptor signaling pathways, and inhibiting epidermal growth factor receptor (EGFR) kinase activity. In addition, IFI6 is highly expressed in autoimmune diseases and malignant tumors and is associated with proliferation, metastasis, and poor prognosis. In this review, we aim to highlight IFI6 as a potential key target in disease diagnosis and treatment.

of 83